X. Yang, P. Yang, J. Shen, E. Osaka, E. Choy et al., Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925, Br J Cancer, vol.110, pp.2896-904, 2014.

W. J. Li and G. , Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance, Oncol Lett, vol.9, issue.2, pp.940-944, 2015.

J. Posthumadeboer, B. J. Van-royen, and M. N. Helder, Mechanisms of therapy resistance in osteosarcoma: a review, Oncol Discov, pp.1-8, 2013.

Z. Duan, Y. Gao, J. Shen, E. Choy, G. Cote et al., miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo, Mol Oncol, vol.11, issue.2, pp.151-166, 2017.

S. S. Bielack, S. Smeland, J. S. Whelan, N. Marina, G. Jovic et al.,

D. Methotrexate and C. , MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, J Clin Oncol, vol.33, issue.20, pp.2279-87, 2015.

H. He, J. Ni, and J. Huang, Molecular mechanisms of chemoresistance in osteosarcoma (Review), Oncol Lett, vol.7, pp.1352-62, 2014.

L. Ottaviano, K. Schaefer, M. Gajewski, W. Huckenbeck, S. Baldus et al., Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort, Genes, Chromosom Cancer, vol.49, pp.40-51, 2010.

S. U. Lauvrak, E. Munthe, S. H. Kresse, E. W. Stratford, H. M. Namløs et al., Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes, Br J Cancer, vol.109, pp.2228-2264, 2013.

M. E. Marques-da-costa, E. Daudigeos-dubus, A. Gomez-brouchet, O. Bawa, V. Rouffiac et al., Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice, Cancer Med, vol.7, issue.3, pp.665-676, 2018.

Ö. Uluçkan, L. Bakiri, and E. F. Wagner, Characterization of Mouse Model-Derived Osteosarcoma (OS) Cells In Vitro and In Vivo, Methods Mol Biol, vol.26, pp.297-305, 2015.

E. Daudigeos-dubus, L. E. Dret, L. Rouffiac, V. Bawa, O. Leguerney et al., Establishment and characterization of new orthotopic and metastatic neuroblastoma models, In Vivo, vol.28, pp.425-459, 2014.

A. B. Olshen, E. S. Venkatraman, R. Lucito, and M. Wigler, Circular binary segmentation for the analysis of array-based DNA copy number data, Biostatistics, vol.5, pp.557-72, 2004.

A. C. Harttrampf, L. Lacroix, M. Deloger, F. Deschamps, S. Puget et al., Molecular Screening for Cancer Treatment Optimization

, Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial, Clin Cancer Res, vol.23, issue.20, pp.6101-6112, 2017.

R. Patro, G. Duggal, M. I. Love, R. A. Irizarry, and C. Kingsford, Salmon provides fast and bias-aware quantification of transcript expression, Nat Methods, vol.14, pp.417-426, 2017.

M. I. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, vol.15, p.550, 2014.

M. Tsubaki, T. Satou, T. Itoh, M. Imano, M. Komai et al., Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells, Leuk Res, vol.36, pp.1315-1337, 2012.

J. Both, O. Krijgsman, J. Bras, G. R. Schaap, F. Baas et al., Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma, PLoS One, vol.9, p.115835, 2014.

P. Gu, W. Deng, M. Lei, and S. Chang, Single strand DNA binding proteins 1 and 2 protect newly replicated telomeres, Cell Res, vol.23, issue.5, pp.705-724, 2013.

N. Gordon and E. S. Kleinerman, The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases, Cancer Treat Res, vol.152, pp.497-508, 2009.

Y. J. Choi, Y. S. Lee, H. W. Lee, D. M. Shim, and S. W. Seo, Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells, Bone Joint Res, vol.6, pp.186-93, 2017.

E. Capobianco, A. Mora, L. Sala, D. Roberti, A. Zaki et al., Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line, PLoS One, vol.22, issue.4, p.95596, 2014.

D. Fiore, R. Fanale, D. Drago-ferrante, R. Chiaradonna, F. Giuliano et al., Genetic and molecular characterization of the human Osteosarcoma 3AB-OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness, J Cell Physiol, vol.228, pp.1189-201, 2013.

Y. Li, G. Meng, and Q. Guo, Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma, Exp Mol Pathol, vol.84, pp.234-243, 2008.

D. Santos-cavalcanti, A. Meohas, W. Ribeiro-g-de, O. De-sá-lopes, A. C. Gholamin et al., Patient-derived osteosarcoma cells are resistant to methotrexate, PLoS One, vol.12, p.184891, 2017.

M. Serra, G. Reverter-branchat, D. Maurici, S. Benini, J. Shen et al., Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells, Ann Oncol, vol.15, pp.151-60, 2004.

C. M. Hattinger, G. Stoico, F. Michelacci, M. Pasello, I. Scionti et al., Mechanisms of gene amplification and evidence of coamplification in drugresistant human osteosarcoma cell lines, Genes Chromosomes Cancer, vol.48, issue.4, pp.289-309, 2009.

E. Selga, C. Oleaga, S. Ramírez, M. C. De-almagro, V. Noé et al., Networking of differentially expressed genes in human cancer cells resistant to methotrexate, Genome Med, vol.1, issue.9, p.83, 2009.

J. Yang, W. Guo, L. Wang, L. Yu, H. Mei et al., Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model

, Oncol Lett, vol.12, pp.2599-605, 2016.

H. Zahreddine and K. L. Borden, Mechanisms and insights into drug resistance in cancer, Front Pharmacol, vol.4, p.28, 2013.

M. Fanelli, C. M. Hattinger, S. Vella, E. Tavanti, F. Michelacci et al., Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma, Curr Cancer Drug Targets, vol.16, pp.261-74, 2016.

Q. Xiang, W. Chen, M. Ren, J. Wang, H. Zhang et al., Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET, Clin Cancer Res, vol.20, pp.2959-70, 2014.

S. Piperno-neumann, L. Deley, M. Rédini, F. Pacquement, H. Marec-bérard et al., , p.28

P. Petit, Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol.17, pp.1070-80, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01702092

J. J. Wang and G. J. Li, Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells, Genet Mol Res, vol.13, issue.3, pp.5313-5334, 2014.

Y. Zhang, Q. Mai, X. Zhang, C. Xie, and Y. Zhang, Microenvironment Signals and Mechanisms in the Regulation of Osteosarcoma, Osteosarcoma -Biology, Behavior and Mechanisms

V. Creen, K. Biteau, J. Amiaud, C. Dumars, R. Guiho et al., Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling, Am J Cancer Res, vol.7, issue.11, pp.2333-2349, 2017.

M. Serra, K. Scotlandi, M. C. Manara, D. Maurici, P. L. Lollini et al., Establishment and characterization of multidrug-resistant human osteosarcoma cell lines, Anticancer Res, vol.13, pp.323-332, 1993.